MONDAY, Oct. 14, 2024 (HealthDay News) -- As with any new drug, parents and doctors may worry that the use of GLP-1 ...

A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...

The future of the weight loss market might not revolve around GLP-1 drugs.

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

Met With High Demand, the Dual-Product System is Clinically Shown to Increase GLP-1 by 140% on average to Balance Hunger ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs ...